Bisphosphonate Use After Estrogen Receptor-Positive Breast Cancer and Risk of Contralateral Breast Cancer

Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01–04) for women with stage II/III breast cancer

(2011) R. Coleman et al.   BREAST CANCER RESEARCH AND TREATMENT

Use of Bisphosphonates and Risk of Breast Cancer

(2011) Peter Vestergaard et al.   CALCIFIED TISSUE INTERNATIONAL

Zoledronic acid for adjuvant use in patients with breast cancer

(2011) Sigrun Ressler et al.   Expert Review of Anticancer Therapy

Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial

(2011) Michael Gnant et al.   LANCET ONCOLOGY

Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study

(2010) H. Eidtmann et al.   ANNALS OF ONCOLOGY

The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer

(2010) R E Coleman et al.   BRITISH JOURNAL OF CANCER

Bisphosphonates for osteoporosis treatment are associated with reduced breast cancer risk

(2010) P A Newcomb et al.   BRITISH JOURNAL OF CANCER

Can Oral Bisphosphonates Really Reduce the Risk of Breast Cancer in Healthy Women?

(2010) Michael Gnant   JOURNAL OF CLINICAL ONCOLOGY

Oral Bisphosphonate Use and Breast Cancer Incidence in Postmenopausal Women

(2010) Rowan T. Chlebowski et al.   JOURNAL OF CLINICAL ONCOLOGY

Use of Bisphosphonates and Risk of Postmenopausal Breast Cancer

(2010) Gad Rennert et al.   JOURNAL OF CLINICAL ONCOLOGY

Contralateral Second Breast Cancers: Prediction and Prevention

(2010) D. J. Brenner   JNCI-Journal of the National Cancer Institute

Adjuvant Hormonal Therapy for Breast Cancer and Risk of Hormone Receptor-Specific Subtypes of Contralateral Breast Cancer

(2009) C. I. Li et al.   CANCER RESEARCH

Zoledronic Acid Effectively Prevents Aromatase Inhibitor–Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole: Z-FAST Study 36-Month Follow-up Results

(2009) Adam M. Brufsky et al.   Clinical Breast Cancer

Bisphosphonates in the Prevention of Disease Recurrence: Current Results and Ongoing Trials

(2009) M. Gnant   CURRENT CANCER DRUG TARGETS

Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer

(2009) Michael Gnant et al.   NEW ENGLAND JOURNAL OF MEDICINE

Exploring the anti-tumour activity of bisphosphonates in early breast cancer

(2008) M.C. Winter et al.   CANCER TREATMENT REVIEWS

Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy

(2008) Michael Gnant et al.   LANCET ONCOLOGY

Zoledronic acid ameliorates the effects of endocrine therapy on bone health in women with early-stage breast cancer

(2008) Robert E Coleman   Nature clinical practice. Endocrinology & metabolism